Sitemap
In English
/
På Svenska
-
Contact
-
BioInvent has been listed on the NASDAQ OMX Stockholm since 2001. Our projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by high-profile partners.
Home
About BioInvent
Products
Partners
Science
Investors
Media Centre
Strategy
Management Team
Board of Directors
Corporate Citizenship
Careers
Pipeline
Oncology
Clinical Trials
Monoclonal Antibodies
n-CoDeR®
F.I.R.S.T™
Manufacturing
Biologic and Preclinical Expertise
The Share
Financial Reports
Press Releases
Presentations
Investor Information
Corporate Governance
Investor Contact
Subscription Service
Press Releases
Downloads
Events
The Share
»
Share Price Information
Five Year Summary
Subscription Service
Financial Reports
»
Annual Reports and Interim Reports
Prospectuses
Press Releases
Presentations
Investor Information
»
Financial Calendar
Analysts
Ownership
Corporate Governance
»
Articles of Association
General Meetings
Nominating Committee
Board of Directors and Auditors
Committees
Management
Principles of Remuneration
Incentive Programme
Corporate Governance Reports
Investor Contact
Subscription Service
Share Price Information
BioInvent International
SE-223 70 Lund, Sweden Visiting: Sölvegatan 41, Lund, Sweden Tel: +46 (0)46-286 85 50 E-mail:
info@bioinvent.com